Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube, Alison Klein, Julie R. Brahmer et al. · Clinical Cancer Research · 2014 · 2.3K citations · Full text

Medicine, Immunology, Oncology +17

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 787 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Pia M. Challita-Eid, Daulet Satpayev, Peng Yang et al. · Cancer Research · 2016 · 696 citations

Pharmacy, Oncology, Pharmacology +17